
The future of CAR-T
Interested in sponsoring the SIG?
FIND OUT MOREThe Cell & Gene Therapy Insights CAR-T Special Interest Group (SIG) is an invitation-only initiative that brings senior experts together in small, closed-door working groups under the Chatham House Rule to build consensus, set priorities, and produce practical, open-access guidance for the field.
SIG members are invited from pharma, biotech, regulatory agencies, clinical practice, payer organizations, and academia to address one central question:
What has to change for CAR-T to reach the patients it was built for?

After a decade as the flagship modality in cell and gene therapy, CAR-T faces challenges that cut across every approach. Manufacturing is difficult to scale, costs limit access, the evidence base outside hematologic cancers remains thin, and regulatory and reimbursement frameworks are still catching up with new technologies. At the same time, advances in process and analytical technologies, gene delivery, and gene editing, along with expansion into autoimmune disease, are changing what the field can realistically aim for.
The 2026 SIG set out priorities for the next phase of CAR-T and identified the questions the field has yet to answer. In its second year, the SIG will focus on three of these:
Meet the members of the SIG Steering Committee, who advise on the SIG’s focus and discussion topics.

Director, Fate Therapeutics

Vice President and Global Head, Drug Discovery, GenEditBio

Dr. Bersenev received his medical education and certification as a general surgeon in Russia. He holds a PhD in transplantation/ pathology. He gained expertise in immunology, hematology, stem cell biology and published scientific papers during post-doctoral training in the US in Philadelphia at the Thomas Jefferson University and the Children’s Hospital of Philadelphia. He worked as a cell manufacturing specialist at the University of Pennsylvania and trained in clinical cell processing in a GMP cell manufacturing facility and was involved in the manufacture of CAR T-cell products for clinical trials and technology transfer to industry. He has expertise in clinical manufacturing of cellular products for clinical trials, including product and process development, cell processing and culture, operations of academic GMP facility and compliance with regulations. In addition to his position as Director of the Advanced Cell Therapy Lab at Yale-New Haven Hospital, he is an Assistant Professor of Clinical Laboratory Medicine at the Department of Laboratory Medicine at Yale University.
Assistant Professor, Clinical Laboratory Medicine, Yale University
+
Dr. Sven Kili is a respected KOL in healthcare and biotechnology, boasting over 20 years of experience. He began as a surgeon in the NHS, where he gained valuable insights into patient care. Transitioning to Cell and Gene Therapies (CGT), Sven played key roles in leading the development, approval and commercialization of both a cell therapy and the first ex vivo gene therapy. With expertise across all stages of CGT development, he has built companies and teams in both large pharma/biotech and startups. Sven is a partner at Saisei Ventures, a boutique therapeutic venture investment firm focussed on creating and growing innovative companies, including with a focus on the Japanese CGT ecosystem. He also heads his consulting firm, Sven Kili Consulting Ltd., offering strategic guidance to organizations in the biotech and healthcare sectors. Most recently he served as the Chief Development Officer for CCRM (Centre for Commercialization of Regenerative Medicine) and OmniaBio. Sven actively contributes to industry boards and committees, including the BIA CGTAC, Innovation Hubs for Gene Therapy, ISCT, and ARM. Sven holds a visiting chair at UCL (University College London), where he heads the steering committee for a post-grad degree in Cell & Gene Therapy manufacturing and commercialisation. His dedication to advancing regenerative medicine and CGT is reflected in his multifaceted roles and ongoing efforts to shape the future of healthcare through innovation and strategic collaboration.
Partner, Saisei Ventures & Principal, Sven Kili Consulting Ltd
+
Adrian Bot, M.D., Ph.D. is a biopharma executive with three decades of experience in research and development with a focus on immune, cell, gene therapy and nanomedicines, from start up to global, commercial stage companies. Most recently, he was the founding Chief Scientific Officer and Executive Vice President of R&D at Capstan Therapeutics, a company developing next generation RNA-based precision medicines. Previously, he held senior leadership roles at Kite Pharma and Kite — a Gilead Company, including Chief Scientific Officer, Global Head of Translational Medicine and Head of Discovery Research, respectively. At Kite, he contributed to the development of first-in-class CAR T cell therapy products for cancer. Previously, Dr. Bot served in various senior R&D leadership positions at MannKind Corp and Alliance Pharmaceutical Corp, La Jolla, California. He obtained his M.D. in Romania in 1993, his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York in 1998 and subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla, California. Dr. Bot is an inventor with multiple issued patents in the field of immunotherapy, and he authored or co-authored more than 200 peer reviewed manuscripts, abstracts, book chapters and monographs. He serves on the Board of Directors of Cartesian Therapeutics, Immuthera Bio and ImmunoScape, and serves as Advisor for AbbVie Inc, Stand Up 2 Cancer and other organizations. Dr. Bot participated in several exits to date: Kite Pharma initial public offering, Kite Pharma acquisition by Gilead Sciences and Capstan Therapeutics acquisition by AbbVie Inc.
Former CSO, Capstan Therapeutics
+SIG members will be announced in early 2027.
The SIG’s work in 2027 centers on a series of closed-door working groups, taking place from June 14 to July 2. The Cell & Gene Therapy Insights editorial team then turns the consensus reached by members into a series of outputs published in the months that follow, setting out the field’s shared position and priorities.
2027 annual SIG:
June 14 – July 2, 2027 (virtual)
The initiative is formed by a series of small, closed-door working groups over three weeks, each focused on a single priority topic.
Working groups will cover areas such as:
All SIG members meet under the Chatham House Rule. Each working group will produce consensus statements, which will form the basis of the outputs below.
A peer-reviewed white paper on a priority topic identified by the group.
An in-depth, open-access consensus report with strategic recommendations for the field.
These may include webinars, infographics, articles, in-person SIG member gatherings, and report-outs at major cell and gene therapy conferences.
To be kept informed about the progression and development of the SIG outputs, please register your interest.
REGISTER YOUR INTERESTThe SIG’s remit continues well beyond the working groups themselves. Outputs from 2026 include:
2026 CAR-T SIG working group meetings: June 16–17, 2026 (virtual)
The future of CAR-T cell therapy: Special Interest Group meeting report Meeting report Cell Gene Ther. Insights 2026; 12(8). DOI: 10.18609/cgti.2026.098. A 98-page open-access report from the 2026 SIG meeting covering autologous, allogeneic, and in vivo CAR-T across 12 chapters.
The industry speaks: what is the future of CAR-T cell therapy? Poll results Results from six live polls of 38 experts at the 2026 SIG, covering which CAR-T modality will lead the next decade, prospects in solid tumors, barriers to patient access, commercial sustainability, and what the field needs from regulators.
Only two in ten eligible patients receive CAR-T: closing the gap starts in manufacturing Infographic Drawing on the Cell & Gene Therapy Insights CAR-T Special Interest Group, this infographic examines the manufacturing barriers behind that gap and compares three routes to wider access: autologous, allogeneic, and in vivo CAR-T. To hear when each 2027 output is published
REGISTER YOUR INTEREST